Neurocrine Biosciences, Inc. (LON:0K6R)
106.69
+2.04 (1.95%)
At close: Apr 25, 2025
Neurocrine Biosciences Employees
Neurocrine Biosciences had 1,800 employees as of December 31, 2024. The number of employees increased by 400 or 28.57% compared to the previous year.
Employees
1,800
Change (1Y)
400
Growth (1Y)
28.57%
Revenue / Employee
1.05M GBP
Profits / Employee
151.46K GBP
Market Cap
7.93B
Employees Chart
Employees History
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 94,300 |
GSK plc | 68,629 |
Haleon | 24,561 |
Smith & Nephew | 17,349 |
ConvaTec Group | 10,489 |
Hikma Pharmaceuticals | 9,500 |
HUTCHMED (China) | 1,811 |
Oxford Nanopore Technologies | 1,315 |
Neurocrine Biosciences News
- 3 days ago - Neurocrine Biosciences publishes positive data from movement disorder study - Seeking Alpha
- 3 days ago - Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry - PRNewsWire
- 5 days ago - Neurocrine Biosciences: Valbenazine As Adjunctive Therapy Could Stage Comeback In 2025 - Seeking Alpha
- 11 days ago - Neurocrine Biosciences: Recent Selloff Has Created A Potential Buying Opportunity - Seeking Alpha
- 12 days ago - This Triumph Group Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday - Benzinga
- 23 days ago - Neurocrine Biosciences names Sanjay Keswani as chief medical officer - Seeking Alpha
- 23 days ago - Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer - PRNewsWire
- 27 days ago - Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia - PRNewsWire